<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Bioequivalence Tests for Parallel Trial Designs: 2 Arms, 3 Endpoints • SimTOST</title>
<!-- jquery --><script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.7.1/jquery.min.js" integrity="sha512-v2CJ7UaYy4JwqLDIrZUI/4hqeoQieOmAZNXBeQyjo21dadnwR+8ZaIJVT8EE2iyI61OV8e6M8PP2/4hpQINQ/g==" crossorigin="anonymous" referrerpolicy="no-referrer"></script><!-- Bootstrap --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/css/bootstrap.min.css" integrity="sha256-bZLfwXAP04zRMK2BjiO8iu9pf4FbLqX6zitd+tIvLhE=" crossorigin="anonymous">
<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/js/bootstrap.min.js" integrity="sha256-nuL8/2cJ5NDSSwnKD8VqreErSWHtnEP9E7AySL+1ev4=" crossorigin="anonymous"></script><!-- bootstrap-toc --><link rel="stylesheet" href="../bootstrap-toc.css">
<script src="../bootstrap-toc.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous">
<!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- pkgdown --><link href="../pkgdown.css" rel="stylesheet">
<script src="../pkgdown.js"></script><meta property="og:title" content="Bioequivalence Tests for Parallel Trial Designs: 2 Arms, 3 Endpoints">
<!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body data-spy="scroll" data-target="#toc">


    <div class="container template-article">
      <header><div class="navbar navbar-default navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <span class="navbar-brand">
        <a class="navbar-link" href="../index.html">SimTOST</a>
        <span class="version label label-default" data-toggle="tooltip" data-placement="bottom" title="">0.3.0</span>
      </span>
    </div>

    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
<li>
  <a href="../reference/index.html">Reference</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Articles

    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
<li>
      <a href="../articles/intopkg.html">Introduction</a>
    </li>
    <li>
      <a href="../articles/sampleSize_crossover.html">Bioequivalence Tests for 2x2 Cross-Over Trial Designs with Log-Normal Data</a>
    </li>
    <li>
      <a href="../articles/sampleSize_parallel_2A3E.html">Bioequivalence Tests for Parallel Trial Designs: 2 Arms, 3 Endpoints</a>
    </li>
    <li>
      <a href="../articles/sampleSize_parallel_3A1E.html">Bioequivalence Tests for Parallel Trial Designs: 3 Arms, 1 Endpoint</a>
    </li>
    <li>
      <a href="../articles/sampleSize_parallel.html">Bioequivalence Tests for Parallel Trial Designs with Log-Normal Data</a>
    </li>
  </ul>
</li>
<li>
  <a href="../news/index.html">Changelog</a>
</li>
      </ul>
<ul class="nav navbar-nav navbar-right">
<li>
  <a href="https://github.com/smartdata-analysis-and-statistics/SimTOST/" class="external-link">
    <span class="fab fa-github fa-lg"></span>

  </a>
</li>
      </ul>
</div>
<!--/.nav-collapse -->
  </div>
<!--/.container -->
</div>
<!--/.navbar -->



      </header><script src="sampleSize_parallel_2A3E_files/kePrint-0.0.1/kePrint.js"></script><link href="sampleSize_parallel_2A3E_files/lightable-0.0.1/lightable.css" rel="stylesheet">
<div class="row">
  <div class="col-md-9 contents">
    <div class="page-header toc-ignore">
      <h1 data-toc-skip>Bioequivalence Tests for Parallel Trial Designs:
2 Arms, 3 Endpoints</h1>
                        <h4 data-toc-skip class="author">Thomas
Debray</h4>
            
            <h4 data-toc-skip class="date">January 08, 2025</h4>
      
      <small class="dont-index">Source: <a href="https://github.com/smartdata-analysis-and-statistics/SimTOST/blob/main/vignettes/sampleSize_parallel_2A3E.Rmd" class="external-link"><code>vignettes/sampleSize_parallel_2A3E.Rmd</code></a></small>
      <div class="hidden name"><code>sampleSize_parallel_2A3E.Rmd</code></div>

    </div>

    
    
<div class="section level2">
<h2 id="introduction">Introduction<a class="anchor" aria-label="anchor" href="#introduction"></a>
</h2>
<p>In many studies, it is necessary to evaluate equivalence across
multiple primary variables. For instance, the European Medicines Agency
(EMA) recommends demonstrating equivalence for both <strong>Area Under
the Curve</strong> (AUC) and <strong>maximum concentration</strong>
(Cmax) when assessing pharmacokinetic properties.</p>
<p>When multiple primary endpoints are involved, a decision must be made
on the desired criteria for equivalence:</p>
<ul>
<li>Equivalence for All Primary Endpoints
<ul>
<li>This is the most common setting and is often referred to as having
<em>multiple co-primary endpoints</em>.</li>
<li>Equivalence must be demonstrated for <strong>all</strong> endpoints
to conclude overall equivalence.</li>
</ul>
</li>
<li>Equivalence for At Least One Primary Endpoint
<ul>
<li>Known as having <em>multiple primary endpoints</em>.</li>
<li>Equivalence is required for <strong>at least one</strong> endpoint
to meet the study’s objectives.</li>
</ul>
</li>
</ul>
<p>This vignette presents advanced techniques for calculating sample
size in parallel trial designs involving three treatment arms and two
endpoints. Specifically, it focuses on bioequivalence testing between a
new treatment (SB2) and a reference drug (Remicade) administered in two
distinct locations (EU_Remicade and USA_Remicade).</p>
<p>As an illustrative example, we consider published data from the
phase-1 trial <a href="https://clinicaltrials.gov/study/NCT01922336#study-overview" class="external-link">NCT01922336</a>.
This trial assessed the pharmacokinetics of SB2 compared to its
EU-sourced reference product. The following outcomes were reported
following a single dose of SB2 or its EU reference product <span class="citation">(<a href="#ref-shin_randomized_2015">Shin et al.
2015</a>)</span>:</p>
<table class="table table table-striped" style="margin-left: auto; margin-right: auto;">
<caption>
Primary PK measures between test and reference product. Data represent
arithmetic mean +- standard deviation.
</caption>
<thead><tr>
<th style="text-align:left;">
PK measure
</th>
<th style="text-align:left;">
SB2
</th>
<th style="text-align:left;">
Remicade (EU)
</th>
</tr></thead>
<tbody>
<tr>
<td style="text-align:left;">
AUCinf
(<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mi>μ</mi><annotation encoding="application/x-tex">\mu</annotation></semantics></math>g*h/mL)
</td>
<td style="text-align:left;">
38,703
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mo>±</mo><annotation encoding="application/x-tex">\pm</annotation></semantics></math>
11,114
</td>
<td style="text-align:left;">
39,360
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mo>±</mo><annotation encoding="application/x-tex">\pm</annotation></semantics></math>
12,332
</td>
</tr>
<tr>
<td style="text-align:left;">
AUClast
(<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mi>μ</mi><annotation encoding="application/x-tex">\mu</annotation></semantics></math>g*h/mL)
</td>
<td style="text-align:left;">
36,862
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mo>±</mo><annotation encoding="application/x-tex">\pm</annotation></semantics></math>
9133
</td>
<td style="text-align:left;">
37,022
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mo>±</mo><annotation encoding="application/x-tex">\pm</annotation></semantics></math>
9398
</td>
</tr>
<tr>
<td style="text-align:left;">
Cmax
(<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mi>μ</mi><annotation encoding="application/x-tex">\mu</annotation></semantics></math>g/mL)
</td>
<td style="text-align:left;">
127.0
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mo>±</mo><annotation encoding="application/x-tex">\pm</annotation></semantics></math>
16.9
</td>
<td style="text-align:left;">
126.2
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mo>±</mo><annotation encoding="application/x-tex">\pm</annotation></semantics></math>
17.9
</td>
</tr>
</tbody>
</table>
</div>
<div class="section level2">
<h2 id="methodology-and-assumptions">Methodology and Assumptions<a class="anchor" aria-label="anchor" href="#methodology-and-assumptions"></a>
</h2>
<p>The bioequivalence analysis focuses on two key pharmacokinetic
endpoints:</p>
<ul>
<li>AUCinf: Area Under the Curve (infinity)</li>
<li>Cmax: Maximum concentration</li>
</ul>
<p>For both endpoints, the analysis assumes that:</p>
<ul>
<li>Summary data (e.g., mean and standard deviation) are available on
the original scale.</li>
<li>These data are provided for each treatment arm.</li>
</ul>
<p>To evaluate bioequivalence, we apply the
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi>%</mi><mi>/</mi><mn>125</mn><mi>%</mi></mrow><annotation encoding="application/x-tex">80\%/125\%</annotation></semantics></math>
rule, which defines equivalence bounds relative to the reference mean.
The evaluation is conducted using a one-sided significance level of 5%,
with a target statistical power of 90%.</p>
</div>
<div class="section level2">
<h2 id="testing-the-difference-of-means-dom-for-multiple-co-primary-endpoints">Testing the Difference of Means (DOM) for multiple Co-primary
Endpoints<a class="anchor" aria-label="anchor" href="#testing-the-difference-of-means-dom-for-multiple-co-primary-endpoints"></a>
</h2>
<p>In biosimilar development, it is important to demonstrate equivalence
across all relevant doses, routes of administration, patient
populations, and endpoints. To establish equivalence between two
treatments, the difference in means for each endpoint,
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msubsup><mi>μ</mi><mi>T</mi><mrow><mo stretchy="true" form="prefix">(</mo><mi>j</mi><mo stretchy="true" form="postfix">)</mo></mrow></msubsup><mo>−</mo><msubsup><mi>μ</mi><mi>R</mi><mrow><mo stretchy="true" form="prefix">(</mo><mi>j</mi><mo stretchy="true" form="postfix">)</mo></mrow></msubsup></mrow><annotation encoding="application/x-tex">\mu_{T}^{(j)} - \mu_{R}^{(j)}</annotation></semantics></math>,
must lie within a predefined equivalence margin around zero for all
primary endpoints.</p>
<div class="section level3">
<h3 id="hypotheses">Hypotheses<a class="anchor" aria-label="anchor" href="#hypotheses"></a>
</h3>
<p>The null and alternative hypotheses for the equivalence test are as
follows:</p>
<p>Null Hypothesis
(<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><msub><mi>H</mi><mn>0</mn></msub><annotation encoding="application/x-tex">H_0</annotation></semantics></math>):
At least one endpoint does not meet the equivalence criteria:</p>
<p><math display="block" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>0</mn></msub><mo>:</mo><msubsup><mi>μ</mi><mi>T</mi><mrow><mo stretchy="true" form="prefix">(</mo><mi>j</mi><mo stretchy="true" form="postfix">)</mo></mrow></msubsup><mo>−</mo><msubsup><mi>μ</mi><mi>R</mi><mrow><mo stretchy="true" form="prefix">(</mo><mi>j</mi><mo stretchy="true" form="postfix">)</mo></mrow></msubsup><mo>≤</mo><msub><mi>E</mi><mi>L</mi></msub><mspace width="0.222em"></mspace><mspace width="0.222em"></mspace><mtext mathvariant="normal">or</mtext><mspace width="0.222em"></mspace><mspace width="0.222em"></mspace><msubsup><mi>μ</mi><mi>T</mi><mrow><mo stretchy="true" form="prefix">(</mo><mi>j</mi><mo stretchy="true" form="postfix">)</mo></mrow></msubsup><mo>−</mo><msubsup><mi>μ</mi><mi>R</mi><mrow><mo stretchy="true" form="prefix">(</mo><mi>j</mi><mo stretchy="true" form="postfix">)</mo></mrow></msubsup><mo>≥</mo><msub><mi>E</mi><mi>U</mi></msub><mspace width="1.0em"></mspace><mtext mathvariant="normal">for at least one</mtext><mspace width="0.278em"></mspace><mi>j</mi></mrow><annotation encoding="application/x-tex">H_0: \mu_T^{(j)} - \mu_R^{(j)} \le E_L ~~ \text{or}~~ \mu_T^{(j)} - \mu_R^{(j)} \ge E_U \quad \text{for at least one}\;j</annotation></semantics></math></p>
<p>Alternative Hypothesis
(<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><msub><mi>H</mi><mn>1</mn></msub><annotation encoding="application/x-tex">H_1</annotation></semantics></math>):
All endpoints meet the equivalence criteria:</p>
<p><math display="block" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>1</mn></msub><mo>:</mo><msub><mi>E</mi><mi>L</mi></msub><mo>&lt;</mo><msubsup><mi>μ</mi><mi>T</mi><mrow><mo stretchy="true" form="prefix">(</mo><mi>j</mi><mo stretchy="true" form="postfix">)</mo></mrow></msubsup><mo>−</mo><msubsup><mi>μ</mi><mi>R</mi><mrow><mo stretchy="true" form="prefix">(</mo><mi>j</mi><mo stretchy="true" form="postfix">)</mo></mrow></msubsup><mo>&lt;</mo><msub><mi>E</mi><mi>U</mi></msub><mspace width="1.0em"></mspace><mtext mathvariant="normal">for all</mtext><mspace width="0.278em"></mspace><mi>j</mi></mrow><annotation encoding="application/x-tex">H_1: E_L&lt;\mu_{T}^{(j)}-\mu_{R}^{(j)} &lt; E_U \quad\text{for all}\;j</annotation></semantics></math></p>
<p>The null hypothesis
(<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><msub><mi>H</mi><mn>0</mn></msub><annotation encoding="application/x-tex">H_0</annotation></semantics></math>)
is rejected if, and only if, all null hypotheses associated with the
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mi>K</mi><annotation encoding="application/x-tex">K</annotation></semantics></math>
primary endpoints are rejected at a significance level of
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mi>α</mi><annotation encoding="application/x-tex">\alpha</annotation></semantics></math>.
This ensures that equivalence is established across all endpoints
simultaneously.</p>
</div>
<div class="section level3">
<h3 id="statistical-considerations">Statistical Considerations<a class="anchor" aria-label="anchor" href="#statistical-considerations"></a>
</h3>
<ul>
<li>
<strong>Type I Error Control</strong>: Since rejection of
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><msub><mi>H</mi><mn>0</mn></msub><annotation encoding="application/x-tex">H_0</annotation></semantics></math>
requires all individual null hypotheses to be rejected, there is no need
for multiplicity adjustments. The Type I error rate is controlled by the
design.</li>
<li>
<strong>Impact on Power</strong>: Requiring equivalence across
multiple endpoints decreases the overall power of the test. The Type II
error increases as the number of primary endpoints
(<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mi>K</mi><annotation encoding="application/x-tex">K</annotation></semantics></math>)
grows, which can make equivalence testing more challenging <span class="citation">(<a href="#ref-mielke_sample_2018">Mielke et al.
2018</a>)</span>.</li>
</ul>
</div>
<div class="section level3">
<h3 id="independent-testing-of-pharmacokinetic-pk-measures">Independent Testing of Pharmacokinetic (PK) Measures<a class="anchor" aria-label="anchor" href="#independent-testing-of-pharmacokinetic-pk-measures"></a>
</h3>
<p>If each pharmacokinetic (PK) measure is tested independently, the
following sample sizes would be required for each endpoint to achieve a
5% significance level:</p>
<div class="sourceCode" id="cb1"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="kw"><a href="https://rdrr.io/r/base/library.html" class="external-link">library</a></span><span class="op">(</span><span class="va"><a href="https://github.com/smartdata-analysis-and-statistics/SimTOST" class="external-link">SimTOST</a></span><span class="op">)</span></span>
<span></span>
<span><span class="co"># Sample size calculation for AUCinf</span></span>
<span><span class="op">(</span><span class="va">sim_AUCinf</span> <span class="op">&lt;-</span> <span class="fu"><a href="../reference/sampleSize.html">sampleSize</a></span><span class="op">(</span></span>
<span>  power <span class="op">=</span> <span class="fl">0.9</span>,                                <span class="co"># Target power</span></span>
<span>  alpha <span class="op">=</span> <span class="fl">0.05</span>,                               <span class="co"># Significance level</span></span>
<span>  arm_names <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"SB2"</span>, <span class="st">"EU_Remicade"</span><span class="op">)</span>,        <span class="co"># Names of trial arms</span></span>
<span>  list_comparator <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span><span class="st">"EMA"</span> <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"SB2"</span>, <span class="st">"EU_Remicade"</span><span class="op">)</span><span class="op">)</span>,  <span class="co"># Comparator configuration</span></span>
<span>  mu_list <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span><span class="st">"SB2"</span> <span class="op">=</span> <span class="fl">38703</span>, <span class="st">"EU_Remicade"</span> <span class="op">=</span> <span class="fl">39360</span><span class="op">)</span>,     <span class="co"># Mean values</span></span>
<span>  sigma_list <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span><span class="st">"SB2"</span> <span class="op">=</span> <span class="fl">11114</span>, <span class="st">"EU_Remicade"</span> <span class="op">=</span> <span class="fl">12332</span><span class="op">)</span>,  <span class="co"># Standard deviation values</span></span>
<span>  list_lequi.tol <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span><span class="st">"EMA"</span> <span class="op">=</span> <span class="fl">0.80</span><span class="op">)</span>,        <span class="co"># Lower equivalence margin</span></span>
<span>  list_uequi.tol <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span><span class="st">"EMA"</span> <span class="op">=</span> <span class="fl">1.25</span><span class="op">)</span>,        <span class="co"># Upper equivalence margin</span></span>
<span>  ncores <span class="op">=</span> <span class="fl">1</span>,                                 <span class="co"># Number of computation cores</span></span>
<span>  nsim <span class="op">=</span> <span class="fl">1000</span>                                 <span class="co"># Number of stochastic simulations</span></span>
<span><span class="op">)</span><span class="op">)</span></span>
<span><span class="co">#&gt; ### Sample Size Calculation Results ###</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt; For a trial targeting 90% power with a 5% type-I error.</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt; -------------------------------------------------------------</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt; The total required sample size to achieve 90.5% power is 78 sample units.</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt;  n_drop n_SB2 n_EU_Remicade n_total power power_LCI power_UCI</span></span>
<span><span class="co">#&gt;   &lt;num&gt; &lt;num&gt;         &lt;num&gt;   &lt;num&gt; &lt;num&gt;     &lt;num&gt;     &lt;num&gt;</span></span>
<span><span class="co">#&gt;       0    39            39      78 0.905 0.8847051 0.9221104</span></span>
<span></span>
<span><span class="co"># Sample size calculation for AUClast</span></span>
<span><span class="op">(</span><span class="va">sim_AUClast</span> <span class="op">&lt;-</span> <span class="fu"><a href="../reference/sampleSize.html">sampleSize</a></span><span class="op">(</span></span>
<span>  power <span class="op">=</span> <span class="fl">0.9</span>,                                <span class="co"># Target power</span></span>
<span>  alpha <span class="op">=</span> <span class="fl">0.05</span>,                               <span class="co"># Significance level</span></span>
<span>  arm_names <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"SB2"</span>, <span class="st">"EU_Remicade"</span><span class="op">)</span>,        <span class="co"># Names of trial arms</span></span>
<span>  list_comparator <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span><span class="st">"EMA"</span> <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"SB2"</span>, <span class="st">"EU_Remicade"</span><span class="op">)</span><span class="op">)</span>,  <span class="co"># Comparator configuration</span></span>
<span>  mu_list <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span><span class="st">"SB2"</span> <span class="op">=</span> <span class="fl">36862</span>, <span class="st">"EU_Remicade"</span> <span class="op">=</span> <span class="fl">37022</span><span class="op">)</span>,     <span class="co"># Mean values</span></span>
<span>  sigma_list <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span><span class="st">"SB2"</span> <span class="op">=</span> <span class="fl">9133</span>, <span class="st">"EU_Remicade"</span> <span class="op">=</span> <span class="fl">9398</span><span class="op">)</span>,    <span class="co"># Standard deviation values</span></span>
<span>  list_lequi.tol <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span><span class="st">"EMA"</span> <span class="op">=</span> <span class="fl">0.80</span><span class="op">)</span>,        <span class="co"># Lower equivalence margin</span></span>
<span>  list_uequi.tol <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span><span class="st">"EMA"</span> <span class="op">=</span> <span class="fl">1.25</span><span class="op">)</span>,        <span class="co"># Upper equivalence margin</span></span>
<span>  ncores <span class="op">=</span> <span class="fl">1</span>,                                 <span class="co"># Number of computation cores</span></span>
<span>  nsim <span class="op">=</span> <span class="fl">1000</span>                                 <span class="co"># Number of stochastic simulations</span></span>
<span><span class="op">)</span><span class="op">)</span></span>
<span><span class="co">#&gt; ### Sample Size Calculation Results ###</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt; For a trial targeting 90% power with a 5% type-I error.</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt; -------------------------------------------------------------</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt; The total required sample size to achieve 90.4% power is 54 sample units.</span></span>
<span><span class="co">#&gt; </span></span>
<span><span class="co">#&gt;  n_drop n_SB2 n_EU_Remicade n_total power power_LCI power_UCI</span></span>
<span><span class="co">#&gt;   &lt;num&gt; &lt;num&gt;         &lt;num&gt;   &lt;num&gt; &lt;num&gt;     &lt;num&gt;     &lt;num&gt;</span></span>
<span><span class="co">#&gt;       0    27            27      54 0.904 0.8836248  0.921199</span></span></code></pre></div>
<p>If we were to test each PK measure independently, we would find a
total sample size of 78 for AUCinf, 54 for AUClast, and
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>N</mi><mo>=</mo><mn>20</mn></mrow><annotation encoding="application/x-tex">N=20</annotation></semantics></math>
for Cmax. This means that we would have to enroll 78 + 54
+<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>=</mo><mn>152</mn></mrow><annotation encoding="application/x-tex">20 = 152</annotation></semantics></math>
patients in order to reject
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><msub><mi>H</mi><mn>0</mn></msub><annotation encoding="application/x-tex">H_0</annotation></semantics></math>
at a significance level of 5%.</p>
</div>
</div>
<div class="section level2">
<h2 class="unnumbered" id="references">References<a class="anchor" aria-label="anchor" href="#references"></a>
</h2>
<div id="refs" class="references csl-bib-body hanging-indent" entry-spacing="0">
<div id="ref-mielke_sample_2018" class="csl-entry">
Mielke, Johanna, Byron Jones, Bernd Jilma, and Franz König. 2018.
<span>“Sample <span>Size</span> for <span>Multiple Hypothesis
Testing</span> in <span>Biosimilar Development</span>.”</span>
<em>Statistics in Biopharmaceutical Research</em> 10 (1): 39–49. <a href="https://doi.org/10.1080/19466315.2017.1371071" class="external-link">https://doi.org/10.1080/19466315.2017.1371071</a>.
</div>
<div id="ref-shin_randomized_2015" class="csl-entry">
Shin, Donghoon, Youngdoe Kim, Yoo Seok Kim, Thomas Körnicke, and Rainard
Fuhr. 2015. <span>“A <span>Randomized</span>, <span>Phase I
Pharmacokinetic Study Comparing SB2</span> and <span>Infliximab
Reference Product</span> (<span>Remicade</span><span></span>) in
<span>Healthy Subjects</span>.”</span> <em>BioDrugs</em> 29 (6): 381–88.
<a href="https://doi.org/10.1007/s40259-015-0150-5" class="external-link">https://doi.org/10.1007/s40259-015-0150-5</a>.
</div>
</div>
</div>
  </div>

  <div class="col-md-3 hidden-xs hidden-sm" id="pkgdown-sidebar">

      </div>

</div>



      <footer><div class="copyright">
  <p></p>
<p>Developed by Thomas Debray, Johanna Muñoz, Dewi Amaliah, Biogen Inc.</p>
</div>

<div class="pkgdown">
  <p></p>
<p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.1.1.</p>
</div>

      </footer>
</div>






  </body>
</html>
